Blueprint Medicines (BPMC) PT Raised to $104 at Piper Sandler
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $104.00 (from $78.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
